GlassScriptPhysician profile
Michael Zgrabik
NPI 1477589588
$1,336.84
in general payments reported to CMS, 2019-2025
17 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $428 · 2020: $127 · 2021: $161 · 2022: $330 · 2023: $290.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $290.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $290.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $273.47 | 2019-2023 | Cequa |
| Allergan, INC. | $264.11 | 2019-2021 | |
| Abbvie INC. | $118.86 | 2022-2023 | Lumigan, Vuity, Alphagan P |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $110.67 | 2019-2021 | |
| Biotissue Holdings INC. | $90.88 | 2022 | |
| Novartis Pharmaceuticals Corporation | $72.70 | 2019-2023 | |
| Bausch & Lomb Americas INC. | $71.07 | 2022-2023 | Vyzulta, Lotemax Sm, Prolensa |
| Alcon Vision LLC | $69.70 | 2019-2023 | Clareon |
| Horizon Therapeutics Plc | $66.94 | 2022-2023 | Tepezza |
| Oyster Point Pharma, INC. | $51.06 | 2022-2023 | Tyrvaya |
| Kala Pharmaceuticals, INC. | $38.23 | 2019 | |
| Ocular Therapeutix, INC. | $29.49 | 2021-2023 | Dextenza |
| Genentech USA, INC. | $20.81 | 2022 | |
| Shire North American Group INC | $18.23 | 2019 | |
| Sight Sciences, INC. | $14.57 | 2022 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dutch Ophthalmic, USA | $13.19 | 2021 | |
| Aerie Pharmaceuticals, INC. | $12.86 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Zgrabik listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.